Boehringer Ingelheim at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Boehringer Ingelheim takes part in 1 session at ESMO 2026 in Madrid, and exhibits at Booth 1065. Its program centres on the next generation of targeted cancer therapy aimed at HER2 and DLL3. The topic fits its development of zongertinib for HER2-mutant lung cancer.

OrganizationESMO 2026 Attendance
Boehringer Ingelheim
Ingelheim, Germany
boehringer-ingelheim.com
Large pharmaExhibitor
Family-owned German pharmaceutical company developing oncology drugs such as zongertinib for HER2-mutant lung cancer.
Booth
Exhibiting at Booth 1065
Satellite
Sat Oct 24
18:30–20:00
Boehringer Ingelheim International GmbH - HER2 and DLL3: Shaping the next generation of targeted cancer therapy
Sponsored session · with Catalan Institute of Oncology (ICO)
Lung & thoracic cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Boehringer Ingelheim

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction